Exploring serotonergic psychedelics as a treatment for personality disorders
- 11 March 2025
- journal article
- review article
- Published by Elsevier in Neuropharmacology
- Vol. 272, 110413
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- National Institute on Drug Abuse
- Usona Institute
- Canadian Institutes of Health Research (202110MFE-472921-HTB-272687)
- Heffter Research Institute
This publication has 174 references indexed in Scilit:
- Adverse Events in Studies of Classic PsychedelicsJAMA Psychiatry, 2024
- Single-Dose Psilocybin Treatment for Major Depressive DisorderJAMA, 2023
- Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression DisorderJAMA Oncology, 2023
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderJAMA Psychiatry, 2022
- Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderJAMA Psychiatry, 2021
- Efficacy of Psychotherapies for Borderline Personality DisorderJAMA Psychiatry, 2017
- Psychedelics as Medicines: An Emerging New ParadigmClinical Pharmacology & Therapeutics, 2016
- Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypothesesDrug Testing and Analysis, 2012
- LSD RevisitedArchives of General Psychiatry, 1971
- Lysergic Acid Diethylamide (LSD-25) as a Facilitating Agent in PsychotherapyArchives of General Psychiatry, 1960